present
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
- Implementing advanced technology solutions to optimize data analysis and improve decision-making processes.
- Developed and implemented cutting-edge technology solutions to streamline business operations and enhance profitability.
- Driving technological advancements and implementation for seamless growth and efficiency in the organization.
- Building a company that is sustainable and competitive across all industries.
- Successfully executed strategic plans and successfully led a team to launch innovative new pipelines.
- Optimized website performance through seamless and effective search engine optimization strategies.
- Implementing strategic initiatives to drive company growth and increase revenue targets.